These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23885823)

  • 1. Influenza virosomes as vaccine adjuvant and carrier system.
    Moser C; Müller M; Kaeser MD; Weydemann U; Amacker M
    Expert Rev Vaccines; 2013 Jul; 12(7):779-91. PubMed ID: 23885823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations.
    Moser C; Amacker M; Kammer AR; Rasi S; Westerfeld N; Zurbriggen R
    Expert Rev Vaccines; 2007 Oct; 6(5):711-21. PubMed ID: 17931152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virosomes as a vaccine adjuvant and carrier system.
    Moser C; Amacker M; Zurbriggen R
    Expert Rev Vaccines; 2011 Apr; 10(4):437-46. PubMed ID: 21506642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends.
    Badiee A; Heravi Shargh V; Khamesipour A; Jaafari MR
    Vaccine; 2013 Jan; 31(5):735-49. PubMed ID: 23219436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The virosome concept for influenza vaccines.
    Huckriede A; Bungener L; Stegmann T; Daemen T; Medema J; Palache AM; Wilschut J
    Vaccine; 2005 Jul; 23 Suppl 1():S26-38. PubMed ID: 16026906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza virosomes in vaccine development.
    Huckriede A; Bungener L; Daemen T; Wilschut J
    Methods Enzymol; 2003; 373():74-91. PubMed ID: 14714397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier.
    Kawano M; Matsui M; Handa H
    Expert Rev Vaccines; 2013 Feb; 12(2):199-210. PubMed ID: 23414410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale.
    Rosenthal JA; Chen L; Baker JL; Putnam D; DeLisa MP
    Curr Opin Biotechnol; 2014 Aug; 28():51-8. PubMed ID: 24832075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outer membrane vesicle: a macromolecule with multifunctional activity.
    Moshiri A; Dashtbani-Roozbehani A; Najar Peerayeh S; Siadat SD
    Hum Vaccin Immunother; 2012 Jul; 8(7):953-5. PubMed ID: 22699443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza virosomes as an efficient system for adjuvanted vaccine delivery.
    Glück R; Moser C; Metcalfe IC
    Expert Opin Biol Ther; 2004 Jul; 4(7):1139-45. PubMed ID: 15268680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant and antigen delivery properties of virosomes.
    Glück R; Burri KG; Metcalfe I
    Curr Drug Deliv; 2005 Oct; 2(4):395-400. PubMed ID: 16305442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal adjuvants for human vaccines.
    Alving CR; Beck Z; Matyas GR; Rao M
    Expert Opin Drug Deliv; 2016 Jun; 13(6):807-16. PubMed ID: 26866300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European union regulatory developments for new vaccine adjuvants and delivery systems.
    Sesardic D; Dobbelaer R
    Vaccine; 2004 Jun; 22(19):2452-6. PubMed ID: 15193409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in mucosal immunization using virus-like particles.
    Vacher G; Kaeser MD; Moser C; Gurny R; Borchard G
    Mol Pharm; 2013 May; 10(5):1596-609. PubMed ID: 23548071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
    Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
    Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant formulations for virus-like particle (VLP) based vaccines.
    Cimica V; Galarza JM
    Clin Immunol; 2017 Oct; 183():99-108. PubMed ID: 28780375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platform for the generation of oral vaccines based on protozoan surface proteins.
    Serradell MDC; Rupil LL; Luján HD
    Medicina (B Aires); 2019; 79(Spec 6/1):559-563. PubMed ID: 31864226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostimulating reconstituted influenza virosomes.
    Zurbriggen R
    Vaccine; 2003 Feb; 21(9-10):921-4. PubMed ID: 12547603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-like particle vaccines and adjuvants: the HPV paradigm.
    Buonaguro FM; Tornesello ML; Buonaguro L
    Expert Rev Vaccines; 2009 Oct; 8(10):1379-98. PubMed ID: 19803760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.